LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the cholestasis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat cholestasis.
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Cholestasis: Market overview
Cholestasis can be defined as the reduction in the flow of bile due to the impaired secretion of bile from hepatocytes or because of an obstruction in the flow of bile through intrahepatic or extrahepatic bile ducts. The symptoms of cholestasis include jaundice, light-colored stools, dark urine, and generalized itchiness. Jaundice develops due to the excess bilirubin deposition in the skin, and dark urine can be observed due to the excess bilirubin excretion from kidneys.
According to a senior analyst at Technavio for research on infectious and rare diseases, “Stools may become light colored as the bilirubin passage into the intestine gets blocked, stopping it from being eliminated from the body through stools. Excess fat may be present in stools as bile cannot enter the intestine to digest the fat present in the diet.”
Cholestasis: Segmentation analysis
This market research report segments the cholestasis market based on therapies employed that includes monotherapy and undisclosed, RoA (oral, intravenous, subcutaneous and undisclosed), therapeutic modalities (small molecules, microbiome, monoclonal antibody, protein and undisclosed), targets for drugs under development (sodium-bile acid cotransporter, FXR, PPAR, CD40, chemokine receptor antagonist, FGF, NOX1/4, and undisclosed), MoA (sodium-bile acid cotransporter-inhibitor, FXR agonist, PPAR agonist, CD40 inhibitor, CCR2/CCR5 antagonist, FGF modulator, NOX1/4 inhibitor, and undisclosed), drugs under development (discovery, pre-clinical, phase I/II, phase II, phase II/III, and phase III), and recruitment status (recruiting, not yet recruiting, completed, and NA). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Recruitment volume
- Type of players
- Company Overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at email@example.com.